Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 08 - 21

Efung Honor | Efung Capital Named to [Jiazi Guangnian] 2025-2026 Top 30 Best Healthcare Investment I

On August 20, 2026, Jiazi Guangnian hosted the "Rapids – 2026 Jiazi Gravity X · Technology Industry Investment Conference," where the "2025-2026 China Technology Industry Investment Rankings" were officially released. Efung Capital was honored with the title of 2025-2026 Top 30 Best Healthcare Investment Institutions.In 2026, China's technology investment landscape is navigating new "rapids."Artificial intelligence is accelerating the reshaping of the industrial landscape, with hard tech remaining a core focus of capital. At the same time, valuation syste...

浏览次数：1

查看详情>>

发布时间: 2026 - 08 - 19

Efung News | NDA for Progen's Recombinant Human Serum Albumin Injection Formally Accepted by NMPA

August 18, 2026 – The New Drug Application (NDA) for Progen's independently developed Recombinant Human Serum Albumin Injection (rHSA, indicated for the treatment of cirrhotic ascites) has been formally accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).This acceptance marks the entry of the product's review and approval process into the substantive stage, and represents another key milestone for Progen in its path of independent innovation and industrialization of recombinant protein therapeutics.Feng Capital participated in Progen&...

浏览次数：2

查看详情>>

发布时间: 2026 - 08 - 17

Efung Honor | Efung Capital Selected for Two Awards fromTitan Media Venture Capital

Today, Titan Media Venture Capital unveiled the prestigious "2026 H1 Pioneer List."Efung Capital was honored with dual accolades:Biopharmaceutical Sector TOP20Venture Capital Institution TOP20If one word could define China's venture capital landscape in the first half of 2026, there would be no halftime break—only relentless acceleration.Fundraising operates on a dual-track system. On the RMB side, state-owned capital continues to deploy aggressively. In April alone, 665 new funds were registered, up nearly 60% year-on-year, with state-backed funds averaging nearly RMB 500 m...

浏览次数：3

查看详情>>

发布时间: 2026 - 08 - 10

Efung Hard Talk | From Sequence Rewriting to “Software” Rewriting

Over the past decade, the main thread of gene therapy has been "rewriting hardware"—from gene supplementation to CRISPR gene editing. Their shared logic is direct modification of the DNA itself: either supplying a functional gene or cutting and rewriting genomic sequences. However, this path carries inherent risks, including genotoxicity, off-target effects, and irreversibility.In recent years, a new class of technologies has been rapidly advancing from concept to clinic—epigenome editing. Its hallmark is that it does not alter the DNA sequence but instead rewrites the "software...

浏览次数：4

查看详情>>